What is the recommended management of acute hemorrhage in a trauma patient?

Management of Acute Hemorrhage in Trauma

Administer tranexamic acid 1g IV bolus immediately (within 1 hour of injury, no later than 3 hours post-injury) while simultaneously achieving rapid hemorrhage control through direct compression, tourniquets for extremity bleeding, or immediate surgical/angiographic intervention for internal bleeding. 1, 2

Immediate Hemorrhage Control (First Priority)

The primary goal is stopping the bleeding source as rapidly as possible, as time from injury to intervention directly correlates with mortality 2.

External Bleeding

• Apply direct local compression to all open wounds as first-line intervention 2
• Apply tourniquets for life-threatening extremity bleeding that cannot be controlled by compression alone 2, 3
• Use hemostatic dressings when standard direct pressure fails to control severe bleeding 3

Internal Bleeding - Diagnostic Approach

For patients in hemorrhagic shock with unidentified bleeding source 4, 5:

1. Immediate FAST ultrasound for torso trauma to detect free fluid 4, 5

   • If positive with hemodynamic instability → immediate surgery
   • If hemodynamically stable → proceed to CT for detailed assessment

2. Pelvic X-ray for suspected pelvic fracture

   • If pelvic ring disruption with shock → immediate pelvic stabilization/closure 4
   • If ongoing instability despite stabilization → angiographic embolization or surgical packing 4

3. CT scan only for hemodynamically stable patients 4, 5

Tranexamic Acid Administration (Concurrent Priority)

The most recent and highest quality evidence from the 2025 guideline strongly supports early TXA administration 1:

• Dose: 1g IV bolus within first hour, followed by 1g infusion over 8 hours 1
• Timing is critical: Must be given within 3 hours of injury 1, 6
  • Administration beyond 3 hours increases mortality risk (RR 1.44) 1
  • Maximum benefit when given within first hour
• Indications: Significant hemorrhage defined by systolic BP <90 mmHg OR heart rate >110 bpm, OR clinical judgment of significant bleeding risk 1
• Mortality benefit: Reduces all-cause mortality from 16.0% to 14.5% (RR 0.91), with one-third reduction in hemorrhage-related deaths 1
• Safety: No increased thromboembolic complications reported in CRASH-2 trial 1

Critical pitfall: Do NOT restrict TXA to only the most severely injured—benefit is consistent across probability of death 1

Resuscitation Strategy

Permissive Hypotension

• Target systolic BP 80-100 mmHg until bleeding is surgically controlled in patients WITHOUT brain injury 4
• Avoid hyperventilation and excessive PEEP in hypovolemic patients 4

Fluid Therapy

• Initial crystalloids are acceptable 4
• Transition rapidly to blood products for ongoing hemorrhage

Blood Product Transfusion

• Use 1:1 to 1:2 ratio of Fresh Frozen Plasma to Red Blood Cells 1
• Activate massive transfusion protocol early for hemorrhagic shock
• Monitor with viscoelastic hemostatic assays (VHA) when available to guide factor replacement 1

Monitoring Parameters

Use these to assess bleeding severity and guide resuscitation 4:

• Serum lactate - primary marker for extent of bleeding and shock
• Base deficit - secondary marker for bleeding severity
• Avoid single hematocrit measurements as isolated markers (unreliable) 4

Surgical Timing

Minimize time from injury to operation 4:

• Patients with identified bleeding source and hemorrhagic shock → immediate bleeding control procedure unless initial resuscitation successful 4
• Consider damage control surgery for patients with deep hemorrhagic shock, ongoing bleeding, coagulopathy, hypothermia, or acidosis 4

Special Considerations

Anticoagulated Elderly Patients

For elderly trauma patients on anticoagulants with active bleeding 7:

• Vitamin K antagonists (warfarin): Give 4-factor prothrombin complex concentrate (4F-PCC) + 5mg IV vitamin K for life-threatening bleeding, target INR <1.5
• Dabigatran: Give idarucizumab 5g IV; if unavailable, use activated PCC 50 units/kg
• Rivaroxaban/Apixaban: Give andexanet alfa (dose based on timing/amount of last DOAC dose); if unavailable, use 4F-PCC 2000 units

Avoid These Interventions

• Do NOT use proximal pressure points or limb elevation for hemorrhage control (inadequate evidence) 3
• Do NOT use antithrombin III concentrates (no benefit shown) 4
• Do NOT apply occlusive dressings to open chest wounds (risk of tension pneumothorax) 3

The evidence strongly supports this algorithmic approach, with the 2025 guideline 1 providing the most recent high-quality data on TXA, while the European guidelines 4, 5, 2 establish the framework for systematic hemorrhage control prioritizing rapid intervention and permissive hypotension until definitive bleeding control is achieved.